Specialized consulting firm participating in combined AAPS Annual Meeting and Exposition/

IPF Pharmaceutical Sciences World Congress

(Research Triangle Park, N.C. and New Orleans, La.) ClinPharm Consulting, a specialized consulting firm offering a unique paradigm for empowering drug development pipelines, has announced its participation in the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in New Orleans, Louisiana November 14-18.

ATS 2010: developments in IPF and cystic fibrosis

The FDA's recent refusal of Esbriet and the publication of new guidelines for the treatment of idiopathic pulmonary fibrosis drove considerable interest in this disease at the 2010 meeting of the American Thoracic Society. Furthermore, the approval of the first new inhaled antibiotic for cystic fibrosis in over a decade brought renewed focus on this rare but extremely debilitating disease.

Open source systems lure drug developers

The gradual spread of software automation in drug development may be getting a boost from open source systems. Most e-clinical systems today--from data capture and storage to trial management and operations--are proprietary, despite the excellent work that solutions providers have done to make their products compatible with existing standards-based and de facto standard industry systems.

GSK and Online Communities Create Unique Alliance to Stimulate Open Source Drug Discovery for Malaria

• GSK becomes first company to freely share chemical structures on 13,500 molecules from its compound library

• Alliances formed with leading scientific research communities from private industry and public-domain data provider

World Congress on Osteoporosis highlights changing face of bone health

Datamonitor attended this year's International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market.

Innovative Strategic Approaches: Moving Forward in Combating Diabetes Mellitus Among GCC countries

Researches estimate that, 366 million people - 4.4% of the world's population will be diabetic by 2030. In order to discuss the possible national and international strategies to overturn this trend - International Diabetes Summit will take place from 5th to 6th October in Dubai, UAE.

APS 2010: fibromyalgia newcomer seeks differentiation while prospective player draws nearer

Established drugs such as Cymbalta and Lyrica will serve to restrict uptake of the most recent entrant to the fibromyalgia market, Savella. Accordingly, data presented at this year's American Pain Society Annual Meeting indicate that Savella's marketing companies are endeavoring to differentiate the product from its key competitors in order to maintain uptake and drive sales.

NicOx: FDA panel's negative opinion casts future of osteoarthritis drug into doubt

The FDA advisory committee has issued a negative recommendation for NicOx's naproxcinod. An FDA advisory meeting has voted 16 to one against recommending the potential osteoarthritis drug naproxcinod. The decision comes after the panel found insufficient safety data to support the drug's target indication. While naproxcinod's commercial potential is now uncertain, Datamonitor believes that the announcement further highlights the FDA's enhanced scrutiny of safety in the post-Vioxx era.